Telomir Pharmaceuticals reports Telomir-Zn restores insulin sensitivity in preclinical type 2 diabetes model study
Share
Listen to the news
Telomir Pharmaceuticals reports Telomir-Zn restores insulin sensitivity in preclinical type 2 diabetes model study
  • Telomir Pharmaceuticals disclosed peer-reviewed preclinical results showing its Telomir-Zn candidate improved insulin sensitivity in a Type 2 diabetes model.
  • Results have already been published, supporting the company’s broader metal-homeostasis approach across metabolic disease and oncology programs.
  • Findings indicate Telomir-Zn restored key measures of glucose control, reinforcing its potential to address insulin resistance.
  • Update adds scientific support as Telomir-Zn moves toward a Phase 1/2 study under an FDA-cleared IND in triple-negative breast cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606150800ACCESSWRNAPR_____1176633) on June 15, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending